Diabetic Peripheral Neuropathy: A Patient Overview

Diabetic peripheral neuropathy (DPN) is nerve damage caused by diabetes that most commonly affects the longest nerves in the body — the ones reaching to the feet and lower legs first, then eventually the hands. Roughly half of people living with diabetes will develop some form of DPN over their lifetime, with damage that develops gradually and follows a recognizable stocking-and-glove pattern. This page explains what DPN is, who develops it, what symptoms patients experience, how physicians diagnose it, and what the literature shows about its course.

Who develops diabetic peripheral neuropathy

DPN affects approximately 50% of people with diabetes at some point in their lives, according to the American Diabetes Association's 2017 Position Statement by Pop-Busui and colleagues (PMID 27999003). The condition appears in both type 1 and type 2 diabetes, though the risk factors differ slightly. In type 1 diabetes, disease duration and glycemic control are the dominant risk factors. In type 2 diabetes, additional factors include age at diagnosis, body weight, blood pressure, lipid levels, and cardiovascular disease history, as described by Feldman and colleagues in a 2019 Nature Reviews Disease Primers overview (PMID 31197153).

The probability of developing DPN increases with diabetes duration. People living with diabetes for more than ten years have substantially higher rates of nerve involvement than those diagnosed recently. Prediabetes can also produce peripheral nerve damage, particularly small-fiber neuropathy — Singleton and colleagues found increased prevalence of impaired glucose tolerance in patients presenting with painful sensory neuropathy in a 2001 Diabetes Care study (PMID 11473085). This is why some patients are diagnosed with diabetes only after a neurologist evaluates unexplained nerve symptoms.

DPN is more common in older adults, in people with poor long-term glycemic control (typically measured by hemoglobin A1c), and in those with diabetic complications elsewhere in the body, including diabetic retinopathy and diabetic kidney disease.

What causes the nerve damage

Elevated blood glucose over time damages peripheral nerves through several mechanisms operating in parallel. Hyperglycemia generates advanced glycation end-products that disrupt nerve protein function. The polyol pathway becomes overactive, depleting cellular antioxidants. Oxidative stress builds in nerve tissue, and the small blood vessels supplying nerves with oxygen and nutrients become damaged, causing nerve ischemia. Feldman and colleagues reviewed these mechanisms comprehensively in a 2017 Neuron paper (PMID 28334605).

DPN follows a length-dependent pattern. The longest nerve fibers — those reaching from the spinal cord to the toes — are affected first because they have the most surface area, the highest energy demands, and the greatest vulnerability to metabolic stress. Shorter fibers, including those reaching to the hands, become involved later in the disease course.

What patients experience

The earliest symptoms most often involve the feet: numbness, a feeling of wearing invisible socks, tingling, pins-and-needles, or burning. These symptoms are often worse at night and may interfere with sleep. The affected area typically follows the stocking-and-glove distribution — the feet first, progressing upward.

Symptoms fall into two categories that often coexist. Positive symptoms include burning, tingling, electric-shock sensations, and allodynia — pain from light touch that would not normally be painful. Negative symptoms include numbness, loss of sensation, loss of position sense, and unsteadiness when walking in the dark. Boulton and colleagues described this symptom framework in a 2005 American Diabetes Association statement (PMID 15793206).

DPN also produces non-painful complications that can be more dangerous than the pain itself. Loss of protective sensation in the feet means injuries — small cuts, blisters, burns from hot bath water — go unnoticed and can progress to ulcers and infections. This is why annual foot examinations are a standard component of diabetes care.

Autonomic involvement, when present, adds a separate layer of symptoms: gastroparesis, constipation, diarrhea, bladder dysfunction, sexual dysfunction, dizziness on standing, and abnormal sweating. Spallone and colleagues reviewed cardiovascular autonomic neuropathy in diabetes in a 2011 Diabetes & Metabolism Research and Reviews paper (PMID 21695768). These autonomic symptoms reflect small unmyelinated fiber involvement and may appear independently of the more familiar foot symptoms.

How DPN is diagnosed

The diagnosis typically begins with a physical examination at a routine diabetes care visit. The Toronto Diabetic Neuropathy Expert Group consensus, published by Tesfaye and colleagues in a 2010 Diabetes Care paper, identifies the core bedside elements: small-fiber function testing using pinprick and temperature sensation; large-fiber testing using vibration (128 Hz tuning fork), position sense, and ankle reflexes; and protective sensation screening with a 10-gram monofilament (PMID 20876709). The monofilament test correlates most directly with foot ulceration risk.

When the clinical picture is unclear or the symptom pattern is atypical for length-dependent DPN, additional testing is ordered. Nerve conduction studies and electromyography assess large-fiber pathways and can confirm a length-dependent polyneuropathy pattern, as described in the American Academy of Neurology guidelines by England and colleagues (PMID 19056666). Skin punch biopsy is used when small-fiber neuropathy is suspected, since standard nerve conduction studies do not detect small-fiber damage.

Laboratory testing serves two purposes: confirming that diabetes is contributing and ruling out coexisting causes. Common workup includes hemoglobin A1c, fasting glucose, vitamin B12 with methylmalonic acid, thyroid-stimulating hormone, complete metabolic panel, and serum protein electrophoresis. A person with diabetes can have a second cause of neuropathy in addition to DPN, and the workup is designed to identify both.

What the literature shows about prognosis

The natural history of DPN is generally progressive without intervention. The Diabetes Control and Complications Trial (DCCT) and its follow-up study (EDIC) established that intensive glycemic control in type 1 diabetes reduces the development and progression of clinical neuropathy by approximately 60% (PMID 7887548). Callaghan and colleagues reviewed the evidence for glycemic control and other treatments in a 2012 Lancet Neurology paper, noting a smaller but measurable effect in type 2 diabetes (PMID 22608666).

Once established, DPN may persist even with subsequent glucose normalization, particularly when large-fiber damage has accumulated. Recovery of nerve function is possible with sustained glycemic control, especially when detected early. Some patients have slowly progressive symptoms over decades; others experience more rapid decline. Tesfaye and colleagues found that coexisting cardiovascular disease, hypertension, and dyslipidemia are associated with worse outcomes in type 2 diabetes specifically (PMID 15673800).

Painful DPN and non-painful DPN follow different trajectories. Pain may improve, worsen, or remain stable independent of the underlying nerve damage. Loss of sensation, once established, rarely reverses — which is why foot protection becomes increasingly important as the disease progresses.

For evidence-based information about treatment options for diabetic peripheral neuropathy

A separate clinical guide on this site covers the treatment landscape for DPN — including first-line medications, what to do when those medications stop working, neuromodulation options, and non-pharmacological approaches — and is reviewed by a board-certified physician on our Medical Advisory Board before publication.

⏳ Under review: A clinical guide covering treatment options for this condition is currently under physician review and will publish soon.

Frequently asked questions